India developing indigenous multi-stage Malaria vaccine 'AdFalciVax'
This vaccine is being developed by the Indian Council of Medical Research (ICMR), through its institutes RMRC Bhubaneswar and the National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology's National Institute of Immunology (DBT-NII).
AdFalciVax is a unique malaria vaccine that targets two key stages of Plasmodium falciparum, the parasite responsible for the deadliest form of malaria.
Most existing vaccines only focus on one stage of the parasite's life cycle, but AdFalciVax is designed to provide stronger and longer-lasting protection by targeting both the human infection stage and the stage responsible for transmission through mosquitoes.
In early lab testing, the vaccine has shown excellent results. Scientists believe that it could offer several benefits over current vaccines like RTS, S/AS01 and R21/Matrix-M.
These include broader protection, reduced chances of the parasite escaping the immune response, and improved long-term immunity.
The vaccine also remains stable for over nine months at room temperature, making it easier to store and transport, especially in tropical regions.
Additionally, it uses cost-effective ingredients like alum, which is commonly used as an adjuvant in vaccines.
The vaccine is currently in the preclinical stage. If everything goes as planned, it could take around seven years for the vaccine to be ready for public use.
The development timeline includes manufacturing under strict safety standards, clinical trials, and regulatory approvals.
One of the key innovations of AdFalciVax is that it is made using 'Lactococcus lactis', a safe and well-known bacteria used in vaccine development.
Its design makes it capable of protecting individuals from getting sick while also reducing the spread of malaria within communities.
The ICMR plans to offer the vaccine technology to other organisations and manufacturers under non-exclusive agreements.
This means multiple companies can work on producing the vaccine, helping it reach more people faster once approved.
AdFalciVax is being developed entirely in India, supporting the government's 'Make in India' initiative.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hans India
5 hours ago
- Hans India
India developing indigenous multi-stage Malaria vaccine 'AdFalciVax'
New Delhi: India has taken a major step forward in the fight against malaria with the development of a new indigenous vaccine candidate called AdFalciVax. This vaccine is being developed by the Indian Council of Medical Research (ICMR), through its institutes RMRC Bhubaneswar and the National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology's National Institute of Immunology (DBT-NII). AdFalciVax is a unique malaria vaccine that targets two key stages of Plasmodium falciparum, the parasite responsible for the deadliest form of malaria. Most existing vaccines only focus on one stage of the parasite's life cycle, but AdFalciVax is designed to provide stronger and longer-lasting protection by targeting both the human infection stage and the stage responsible for transmission through mosquitoes. In early lab testing, the vaccine has shown excellent results. Scientists believe that it could offer several benefits over current vaccines like RTS, S/AS01 and R21/Matrix-M. These include broader protection, reduced chances of the parasite escaping the immune response, and improved long-term immunity. The vaccine also remains stable for over nine months at room temperature, making it easier to store and transport, especially in tropical regions. Additionally, it uses cost-effective ingredients like alum, which is commonly used as an adjuvant in vaccines. The vaccine is currently in the preclinical stage. If everything goes as planned, it could take around seven years for the vaccine to be ready for public use. The development timeline includes manufacturing under strict safety standards, clinical trials, and regulatory approvals. One of the key innovations of AdFalciVax is that it is made using 'Lactococcus lactis', a safe and well-known bacteria used in vaccine development. Its design makes it capable of protecting individuals from getting sick while also reducing the spread of malaria within communities. The ICMR plans to offer the vaccine technology to other organisations and manufacturers under non-exclusive agreements. This means multiple companies can work on producing the vaccine, helping it reach more people faster once approved. AdFalciVax is being developed entirely in India, supporting the government's 'Make in India' initiative.
Economic Times
10 hours ago
- Economic Times
Development of indigenous multi-stage Malaria vaccine 'AdFalciVax' is underway
The Indian Council of Medical Research (ICMR), through its Regional Medical Research Centre, Bhubaneswar (RMRCBB) and National Institute of Malaria Research (NIMR), in partnership with the Department of Biotechnology-National Institute of Immunology (DBT-NII), is currently developing a novel recombinant chimeric malaria vaccine candidate, named AdFalciVax. ADVERTISEMENT AdFalciVax is the first indigenous recombinant chimeric malaria vaccine specifically designed to target two critical stages of Plasmodium falciparum, the parasite responsible for the most lethal form of malaria. The vaccine aims to protect against human infection while also reducing vector-borne community transmission of the parasite. According to the release, the vaccine has demonstrated excellent efficacy in the preclinical stage of development. Preclinical data suggest that AdFalciVax may have advantages over existing single-stage vaccines, including broader protection by targeting two vulnerable parasite stages, lower risk of immune evasion, potential for better long-term immunity, and extended thermal stability with functionality maintained for over nine months at room is a recombinant multistage vaccine produced in Lactococcus lactis, designed to protect both individual humans and reduce the community transmission represents one of the most advanced malaria vaccine candidates globally, with a rational design targeting two key stages of the parasite. This vaccine consists of a stable and functional recombinant chimaera between antigenic components that promises dual protection. ADVERTISEMENT ICMR intends to license the technology for AdFalciVax to eligible organisations and manufacturers for further development, manufacture, and commercialisation under non-exclusive agreements. This approach aims to enable wider outreach and maximise public health benefits. All collaborations will adhere to ICMR's Intellectual Property Policy. ADVERTISEMENT As an indigenously developed vaccine candidate that fulfils the Make in India mandate, AdFalciVax holds the potential to contribute substantially to malaria eradication by preventing infection and minimising community information is provided for awareness purposes only. The vaccine candidate is in its early research and development phases and is not yet available for any clinical use or commercialisation. ADVERTISEMENT (You can now subscribe to our Economic Times WhatsApp channel)
&w=3840&q=100)
Business Standard
10 hours ago
- Business Standard
ICMR invites EoIs for tech transfer to commercialise malaria vaccine
The Indian Council of Medical Research (ICMR) has invited expressions of interest (EoI) from eligible companies and manufacturers to undertake the transfer of technology for commercialisation of an indigenous recombinant multi-stage malaria vaccine candidate named AdFalciVax. The vaccine candidate, being developed by ICMR's Regional Medical Research Centre, Bhubaneswar (ICMR-RMRCBB), aims to prevent plasmodium falciparum, a parasite which causes severe and fatal malaria, in humans and minimise its community transmission. According to the EoI, ICMR-RMRCBB will also provide expert guidance and technical support for the production of the vaccine in all phases, effectively accelerating its development and commercialisation. The agreement is proposed to be executed on a non-exclusive basis with single or multiple companies to enable wider outreach of the malaria vaccine for societal benefit and public health use. It added that the development may take at least seven years in four stages with each stage having a six-month buffer time. While ICMR would provide technical support through its team of experienced scientists in study planning and product development, the selected company would be responsible for obtaining all the regulatory approvals, starting from research and development (R&D) for product development to its commercialisation. The Council will also have no financial implications unless otherwise specified, however, its institutes would provide support and facilitation to conduct the R&D and clinical studies of new technology in India. The EoI adds that in case of transfer of technology, ICMR is the sole owner of the said technology, including any underlying Intellectual Properties and commercialisation rights. 'In case of collaboration between ICMR and the company for the joint development of the technology/product, the Background Intellectual Property (BGIP) shall always remain the sole and non-exclusive property of the party generating it,' the EoI said. As part of the agreement, the collaborating company will be required to share technical data with ICMR and participate in all discussions in a professional and mutually agreed-upon manner. 'Subsequent to the execution of the agreement, such companies/manufacturers shall be responsible to pay the royalty at the rate of 2 per cent on net sales, according to the ICMR Guidelines for Technology Development Collaboration,' the medical research body said. According to the World Health Organisation's (WHO) World Malaria Report 2024, India contributes half of all estimated cases in the South East Asia Region, which in turn accounts for 1.5 per cent of the global malaria burden. India currently has access to two WHO-recommended malaria vaccines, Mosquirix and R21/Matrix-M. While the former is manufactured by GlaxoSmithKline (GSK), the latter is manufactured by the Serum Institute of India (SII). Both vaccines are primarily for children in areas with moderate to high malaria transmission. 'Based on preclinical data, AdFalciVax may offer advantages such as broader protection and a lower risk of immune evasion compared to existing single-stage malaria vaccines,' an official in the know said. The pre-clinical validation of the vaccine candidate was conducted in collaboration with the Indian Council of Medical Research-National Institute of Malaria Research, other constituent institutes of ICMR, and the National Institute of Immunology in Delhi, an autonomous research institute of the Department of Biotechnology.
